Biodistribution studies were conducted seven days post-injection in mice bearing breast and colon adenocarcinoma xenografts to evaluate the in vivo pharmacokinetics of 89Zr-DFO-anti-LAMP1 and the IgG control tracer. This evidence concerns the gene LAMP1 and colon adenocarcinoma.